Qingping Xiong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Qingping Xiong has a total of 178 co-authors. Here are the top co-authors by number of shared publications:
Jun Yuan
Jiangsu Key Laboratory of Regional Resource Exploitation and Medicinal Research, Huaiyin Institute of Technology, Huai'an, Jiangsu 223003, PR China
7 shared publicationsYi Jing
Jiangsu Key Laboratory of Regional Specific Resource Pharmaceutical Transformation, Huaiyin Institute of Technology, Huai'an 223003, Jiangsu, PR China
7 shared publicationsGuangzhen Zheng
State Key Laboratory of Traditional Chinese Medicine Syndrome, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, PR China
6 shared publicationsYingying Shi
Jiangsu Key Laboratory of Regional Specific Resource Pharmaceutical Transformation, Huaiyin Institute of Technology, Huai'an, 223003, Jiangsu, PR China
6 shared publicationsShijie Li
Guangdong Provincial Key Laboratory of New Drug Development and Research of Chinese Medicine, Mathematical Engineering Academy of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, China
5 shared publicationsZhuoyue Song
Clinical Medical College of Acupuncture Moxibustion and Rehabilitation, Mathematical Engineering Academy of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, China
5 shared publications
Latest Publications
- Open Access
- 26 August 2026
- Published by Springer Nature in npj Science of Food
Medicinal and edible fungal polysaccharide: sources, preparation, structural characteristics, and health benefits
- 26 August 2026
- Published by Springer Nature in npj Science of Food
Open AccessMedicinal and edible fungal polysaccharide: sources, preparation, structural characteristics, and health benefits
- Open Access
- 17 November 2025
- Published by American Chemical Society (ACS) in Chemical & Biomedical Imaging
- Vol. 4 (4) , 638-647
Donor Modulation of Strong Near-Infrared Lipid-Droplet Probes for in Vivo Diagnosis of Nonalcoholic Fatty Liver Disease
Lipid droplet accumulation is a pathological hallmark of nonalcoholic fatty liver disease (NAFLD); however, the utility of current lipid droplet-targeted fluorescent probes for in vivo diagnosis is hindered by shallow tissue penetration and strong background autofluorescence. To overcome these challenges, here, we report three donor–acceptor–acceptor solvatochromic probes (CTBT-ANPy, PTBT-ANPy, and MOPTBT-ANPy) with tunable electron-donating groups, enabling near-infrared (NIR) imaging of lipid droplets and in vivo NAFLD diagnosis. Owing to multiple intramolecular interactions and restriction of twisted intramolecular charge transfer, these probes exhibit intense NIR emissions (up to 709 nm, quantum yield of 34.2%) in low-polarity media. These lipophilic probes display high lipid-droplet specificity with bright light-up signals and wash-free capacity. With the aid of NIR-emissive MOPTBT-ANPy, in vivo high-contrast fluorescent discrimination of NAFLD in a mouse model was successfully achieved. This study underscores the potential of high-performance NIR probes for noninvasive accurate NAFLD diagnosis and monitoring.
- 17 November 2025
- Published by American Chemical Society (ACS) in Chemical & Biomedical Imaging
- Vol. 4 (4) , 638-647
Open AccessDonor Modulation of Strong Near-Infrared Lipid-Droplet Probes for in Vivo Diagnosis of Nonalcoholic Fatty Liver Disease
Lipid droplet accumulation is a pathological hallmark of nonalcoholic fatty liver disease (NAFLD); however, the utility of current lipid droplet-targeted fluorescent probes for in vivo diagnosis is hindered by shallow tissue penetration and strong background autofluorescence. To overcome these challenges, here, we report three donor–acceptor–acceptor solvatochromic probes (CTBT-ANPy, PTBT-ANPy, and MOPTBT-ANPy) with tunable electron-donating groups, enabling near-infrared (NIR) imaging of lipid droplets and in vivo NAFLD diagnosis. Owing to multiple intramolecular interactions and restriction of twisted intramolecular charge transfer, these probes exhibit intense NIR emissions (up to 709 nm, quantum yield of 34.2%) in low-polarity media. These lipophilic probes display high lipid-droplet specificity with bright light-up signals and wash-free capacity. With the aid of NIR-emissive MOPTBT-ANPy, in vivo high-contrast fluorescent discrimination of NAFLD in a mouse model was successfully achieved. This study underscores the potential of high-performance NIR probes for noninvasive accurate NAFLD diagnosis and monitoring.
- 19 April 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 310, 143380
Key proteins identification of Buyang Huanwu Decoction in regulating macrophage polarization to alleviate atherosclerosis via an integrated strategy combining network pharmacology, batch molecular docking and experimental verification
- 19 April 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 310, 143380
Key proteins identification of Buyang Huanwu Decoction in regulating macrophage polarization to alleviate atherosclerosis via an integrated strategy combining network pharmacology, batch molecular docking and experimental verification
- 9 February 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 343, 119450
An integrative approach for mechanistic insights into the atherosclerotic plaque-stabilizing properties of Danggui Buxue decoction
- 9 February 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 343, 119450
An integrative approach for mechanistic insights into the atherosclerotic plaque-stabilizing properties of Danggui Buxue decoction
- 10 May 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (10) , 8020-8042
Glycyrrhetinic Acid as a Hepatocyte Targeting Ligand-Functionalized Platinum(IV) Complexes for Hepatocellular Carcinoma Therapy and Overcoming Multidrug Resistance
Promising targeted therapy options to overcome drug resistance and side effects caused by platinum(II) drugs for treatment in hepatocellular carcinoma are urgently needed. Herein, six novel multifunctional platinum(IV) complexes through linking platinum(II) agents and glycyrrhetinic acid (GA) were designed and synthesized. Among them, complex 20 showed superior antitumor activity against tested cancer cells including cisplatin resistance cells than cisplatin and simultaneously displayed good liver-targeting ability. Moreover, complex 20 can significantly cause DNA damage and mitochondrial dysfunction, promote reactive oxygen species generation, activate endoplasmic reticulum stress, and eventually induce apoptosis. Additionally, complex 20 can effectively inhibit cell migration and invasion and trigger autophagy and ferroptosis in HepG-2 cells. More importantly, complex 20 demonstrated stronger tumor inhibition ability than cisplatin or the combo of cisplatin/GA with almost no systemic toxicity in HepG-2 or A549 xenograft models. Collectively, complex 20 could be developed as a potential anti-HCC agent for cancer treatment.
- 10 May 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (10) , 8020-8042
Glycyrrhetinic Acid as a Hepatocyte Targeting Ligand-Functionalized Platinum(IV) Complexes for Hepatocellular Carcinoma Therapy and Overcoming Multidrug Resistance
Promising targeted therapy options to overcome drug resistance and side effects caused by platinum(II) drugs for treatment in hepatocellular carcinoma are urgently needed. Herein, six novel multifunctional platinum(IV) complexes through linking platinum(II) agents and glycyrrhetinic acid (GA) were designed and synthesized. Among them, complex 20 showed superior antitumor activity against tested cancer cells including cisplatin resistance cells than cisplatin and simultaneously displayed good liver-targeting ability. Moreover, complex 20 can significantly cause DNA damage and mitochondrial dysfunction, promote reactive oxygen species generation, activate endoplasmic reticulum stress, and eventually induce apoptosis. Additionally, complex 20 can effectively inhibit cell migration and invasion and trigger autophagy and ferroptosis in HepG-2 cells. More importantly, complex 20 demonstrated stronger tumor inhibition ability than cisplatin or the combo of cisplatin/GA with almost no systemic toxicity in HepG-2 or A549 xenograft models. Collectively, complex 20 could be developed as a potential anti-HCC agent for cancer treatment.
- 17 September 2023
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 253 (Pt 3) , 126920
Therapeutic mechanism exploration of polysaccharides from Dendrobium officinale on unilateral ureteral obstruction operation-induced renal fibrosis based on improving oxidative stress injury mediated by AhR/NOX4 pathway
- 17 September 2023
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 253 (Pt 3) , 126920
Therapeutic mechanism exploration of polysaccharides from Dendrobium officinale on unilateral ureteral obstruction operation-induced renal fibrosis based on improving oxidative stress injury mediated by AhR/NOX4 pathway
- 8 July 2023
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 247, 125727
Application of protein/polysaccharide aerogels in drug delivery system: A review
- 8 July 2023
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 247, 125727
Application of protein/polysaccharide aerogels in drug delivery system: A review
- 18 April 2023
- Published by Elsevier in Phytomedicine
- Vol. 115, 154835
Mechanism exploration of 6-Gingerol in the treatment of atherosclerosis based on network pharmacology, molecular docking and experimental validation
- 18 April 2023
- Published by Elsevier in Phytomedicine
- Vol. 115, 154835
Mechanism exploration of 6-Gingerol in the treatment of atherosclerosis based on network pharmacology, molecular docking and experimental validation
- Open Access
Anti-Invasive and Anti-Migratory Effects of Ononin on Human Osteosarcoma Cells by Limiting the MMP2/9 and EGFR-Erk1/2 Pathway
Osteosarcoma is a common malignancy of the bone. Due to its high metastatic properties, osteosarcoma becomes the leading cause of cancer death worldwide. Ononin is an isoflavone glycoside known to have various pharmacological properties, including antioxidant and anti-inflammatory activities. In the present study, we aimed to investigate the efficacy of ononin on osteosarcoma cell migration, invasion, and the underlying mechanisms. The in vitro anti-tumorigenic and anti-migratory properties of ononin were determined by MTT, colony formation, invasion, and migration in MG-63 and U2OS osteosarcoma cell lines. The results were compared with the standard chemotherapeutic drug, doxorubicin (DOX), as a positive control. The dose-dependent manners of ononin treatment increased the expression of apoptosis and inhibition of cell proliferation through the EGFR-Erk1/2 signaling pathways. Additionally, ononin significantly inhibited the invasion and migration of human osteosarcoma cells. For consistency, we used the MG-63-xenograft mice model to confirm the in vivo anti-tumorigenic and anti-migratory efficacy of ononin by inhibiting the protein expressions of EGFR-Erk1/2 and MMP2/9. According to the histological study, ononin had no adverse effect on the liver and kidney. Overall, our findings suggested that ononin could be a potentially effective agent against the development and metastasis of osteosarcoma.
Open AccessAnti-Invasive and Anti-Migratory Effects of Ononin on Human Osteosarcoma Cells by Limiting the MMP2/9 and EGFR-Erk1/2 Pathway
Osteosarcoma is a common malignancy of the bone. Due to its high metastatic properties, osteosarcoma becomes the leading cause of cancer death worldwide. Ononin is an isoflavone glycoside known to have various pharmacological properties, including antioxidant and anti-inflammatory activities. In the present study, we aimed to investigate the efficacy of ononin on osteosarcoma cell migration, invasion, and the underlying mechanisms. The in vitro anti-tumorigenic and anti-migratory properties of ononin were determined by MTT, colony formation, invasion, and migration in MG-63 and U2OS osteosarcoma cell lines. The results were compared with the standard chemotherapeutic drug, doxorubicin (DOX), as a positive control. The dose-dependent manners of ononin treatment increased the expression of apoptosis and inhibition of cell proliferation through the EGFR-Erk1/2 signaling pathways. Additionally, ononin significantly inhibited the invasion and migration of human osteosarcoma cells. For consistency, we used the MG-63-xenograft mice model to confirm the in vivo anti-tumorigenic and anti-migratory efficacy of ononin by inhibiting the protein expressions of EGFR-Erk1/2 and MMP2/9. According to the histological study, ononin had no adverse effect on the liver and kidney. Overall, our findings suggested that ononin could be a potentially effective agent against the development and metastasis of osteosarcoma.